Athena Uzzo, SVP of Customer Experience at Claritas Rx, on how the company turns complex healthcare data into actionable insights for pharmaceutical manufacturers.

The pathway from drug development to patient access remains one of healthcare’ s most persistent challenges. As therapies become increasingly sophisticated, so does the complexity of ensuring treatments reach the right patients at the right time.

Specialty and Rare Disease data experts at Claritas Rx have been addressing this challenge since 2011, when they began improving how biopharmaceutical manufacturers understand their specialty product performance. The company has evolved from a smallchannel data consultancy to a leader in patient-level data integration and analytics, with a client base that spans emerging biotechnology companies launching first specialty products to global manufacturers with established portfolios.

This data-driven approach has transformed how patient journeys are understood through the company’ s work with global pharmaceutical company Servier. What began in 2020 as a focused collaboration on two oncology drugs has grown into a partnership spanning Servier’ s entire cancer treatment portfolio.

Athena Uzzo, Senior Vice President of Customer Experience at Claritas Rx, describes the relationship as“ a collaborative partnership” built around answering Servier’ s specific business questions.

“ We handle the data aggregation and work with all of their partners across those brands, and then also deliver the analytical insights,” she says.

Claritas Rx was founded with a specific mission.“ Our company started with the mission to ensure that patients with chronic and life-threatening diseases receive the support that enables the greatest benefit from their therapy,” Athena explains.

The Claritas Rx data model provides actionable insights for Servier teams

The core differentiation for Claritas Rx comes from its approach to data integration. This flexibility extends beyond data integration to how information is presented.“ We’ re able to do this for customers that have a single drug on the market, as well as for customers that have multiple brands where we look at brand and disease-specific insights,” she notes.